Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    tocagen
Show Display Options
Rank Status Study
1 Not yet recruiting A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
Condition: Newly Diagnosed High Grade Glioma (HGG)
Interventions: Biological: Toca 511;   Drug: Toca FC
2 Recruiting P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Interventions: Biological: Toca 511;   Drug: Toca FC;   Drug: Lomustine;   Drug: Temozolomide;   Biological: Bevacizumab
3 Recruiting A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors
Conditions: Metastatic Colorectal Cancer;   Metastatic Renal Cell Carcinoma;   Metastatic Melanoma;   Brain Metastasis;   Locally Advanced or Metastatic Pancreatic Cancer;   Locally Advanced or Metastatic Breast Cancer
Interventions: Biological: Toca 511;   Drug: Toca FC
4 Active, not recruiting Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma
Intervention: Biological: Toca 511
5 Active, not recruiting Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma
Intervention: Biological: Toca 511
6 Active, not recruiting A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma
Interventions: Biological: Toca 511;   Drug: 5-FC

Indicates status has not been verified in more than two years